-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
UroGen Pharma Ltd. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2017 to Q3 2025.
- UroGen Pharma Ltd. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was -$1.05M, a 1258% decline year-over-year.
- UroGen Pharma Ltd. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $3M, a 25.6% decline year-over-year.
- UroGen Pharma Ltd. annual Income Tax Expense (Benefit) for 2024 was $2.83M, a 27.8% decline from 2023.
- UroGen Pharma Ltd. annual Income Tax Expense (Benefit) for 2023 was $3.92M, a 123% increase from 2022.
- UroGen Pharma Ltd. annual Income Tax Expense (Benefit) for 2022 was $1.76M, a 21.1% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)